课题基金 / 基金详情

项目摘要

项目成果

JOSEPH Benjamin RUCKER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):由于其在细胞信号传导和人类疾病中的重要性,整体膜蛋白如G蛋白偶联受体(gpcr)和离子通道占现有药物靶点的40%以上。识别膜蛋白构象依赖性表位的单克隆抗体(mab)通常是最有价值的抗体类型,因为它们通常与受体的关键结构结合,可以用于检测或抑制受体。然而,针对膜蛋白的构象依赖性、抑制性单克隆抗体的开发尤其困难,因为与可溶性蛋白不同,大多数膜蛋白依赖于脂质环境来维持其原生的三级和四级(低聚物)结构。膜蛋白通常难以纯化,通常在细胞表面以低浓度表达,并且通常不能用线性肽表示。开发用于治疗、诊断和研究的单克隆抗体需要新的方法。在这里,我们建议使用一种新颖的技术,脂质,以一种适合免疫的格式捕获和浓缩结构完整的膜蛋白。利用脂质颗粒开发针对细胞膜蛋白的抗体的概念是建立在历史上成功使用病毒颗粒作为疫苗的基础上的。
英文摘要
DESCRIPTION (provided by applicant): Because of their importance in cell signaling and human disease, integral membrane proteins such as G protein-coupled receptors (GPCRs) and ion channels comprise over 40% of existing drug targets. Monoclonal antibodies (MAbs) that recognize conformation-dependent epitopes on membrane proteins are usually the most valuable type of antibody because they often bind to critical structures of the receptor that can be exploited for its detection or inhibition. However, the development of conformation-dependent, inhibitory MAbs against membrane proteins is especially difficult because, unlike soluble proteins, most membrane proteins are dependent on a lipid environment to maintain their native tertiary and quaternary (oligomeric) structures. Membrane proteins are often difficult to purify, often express at low concentrations on the cell surface, and are usually poorly represented by linear peptides. New approaches are needed to develop such MAbs for therapeutic, diagnostic, and research applications. Here we propose to use a novel technology, the Lipoparticle, to capture and concentrate structurally intact membrane proteins in a format amenable to immunization. The concept of using Lipoparticles to develop antibodies against cellular membrane proteins builds on the historic use of viral particles as successful vaccines. PUBLIC HEALTH RELEVANCE: This proposal will result in monoclonal antibodies against important membrane protein targets for therapeutic development, diagnostics, and biomedical research. Lipoparticles optimized as immunogens will be developed as commercial products.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10482193
  • 项目类别:
  • 资助金额:
    $59.99万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10631161
  • 项目类别:
  • 资助金额:
    $70.93万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
  • 批准号:
    10318547
  • 项目类别:
  • 资助金额:
    $47.48万
  • 财政年份:
    2021
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Identifying Agonist MAbs against GPCRs
  • 批准号:
    9756430
  • 项目类别:
  • 资助金额:
    $13.22万
  • 财政年份:
    2018
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
海外基金